Printer-friendly versionPrinter-friendly version

Prevention and control of perinatal hepatitis B virus (HBV) transmission in the WHO European Region

CDC - UNICEF - VHPB - WHO

Istanbul, Turkey, March 15-17, 2006

Overall goal for the meeting

To contribute to further prevention and control of perinatal hepatitis B virus (HBV) transmission in the countries of the European Region of the World Health Organization (WHO), by highlighting the advantages of newborn hepatitis B vaccination based on scientific evidence, and by sharing examples, experience, and knowledge regarding prevention of mother-to-child transmission of HBV.

Wednesday, March 15, 2006

Session 1 Opening and objectives

Chair: Nedret Emiroglu and Ludmila Mosina

09.00-09.10

  • Welcome and review of the meeting objectives
  • Review of the objectives of the meeting
    • Provide participants with an overview of the current epidemiology of perinatal HBV transmission globally and in the WHO European Region.
    • Provide participants with an overview of the scientific evidence on prevention and control of perinatal HBV transmission through vaccination.
    • Provide an overview of countries in the WHO European Region with hepatitis B birth dose administration and maternal screening.
    • Give an overview of examples and experiences of countries in the WHO European Region regarding prevention and control of perinatal HBV transmission.
    • Identify challenges and tresholds experienced while improving perinatal HBV transmission.
    • Discuss lessons learnt and opportunities. 
    • Discuss the role of various partner agencies and organisations in prevention and control of perinatal HBV transmission in the WHO European Region.
    • Discuss the concept of prevention of perinatal HBV transmission against the broader background of mother-and-child health.
  • Pre-meeting document 405 Kb (.pdf)

Session 2 Epidemiology of perinatal HBV transmission

Chair: Nedret Emiroglu and Ludmila Mosina

09.10-09.40
Hepatitis B disease burden: a model for global estimates and impact of vaccination 132 Kb (.pdf) загрузите русскую версию
Susan Wang, Atlanta, Georgia, USA

09.40-10.00
Magnitude of perinatal HBV transmission in the Central Asian Republics 1,659 Kb (.pdf)  загрузите русскую версию
Ludmila Mosina, Atlanta, Georgia, USA
 
10.00-10.20
Overview of HBV Infections and the vaccination policy in Turkey 532 Kb (.pdf)  загрузите русскую версию
Meral Çiblak and Selim Badur, Istanbul, Turkey

10.35-11.00
Coffee break

Session 3  Scientific evidence on control and prevention of perinatal HBV transmission through immunisation

Chair: Andrei Lobanov and Wolfgang Jilg

11.00-11.30
Effectiveness of newborn hepatitis B vaccination programmes in achieving a reduction of chronic carriage – timing of the birth dose – administration of HBIg: a review  1,097 Kb (.pdf) загрузите русскую версию
Francis André, Belgium

11.30-11.50
Are immunogenicity and protective efficacy of hepatitis B vaccine related to different administration schedules? 625 Kb (.pdf) загрузите русскую версию
Voranush Chongsrisawat, Bangkok, Thailand

11.50-12.00
Long term efficacy of hepatitis B vaccination of newborns from HBs Ag positive mothers in Thailand 58 Kb (.pdf) загрузите русскую версию
Bernard Hoet, Belgium

12.05- 14.00
Lunch
 
Session 4 Prevention and control of perinatal HBV transmission: country status and experiences

Chair: Michael Favorov and Paolo Bonanni

14.00-14.20
Prevention of perinatal HBV transmission: evaluation of programmes and success stories from the Central Asian Republics – an example from Kazakhstan 1,826 Kb (.pdf) загрузите русскую версию
Michael Favorov, Atlanta, Georgia, USA

14.20-14.40
Experience from Armenia 968 Kb (.pdf) загрузите русскую версию
Armen Hayrapetyan, Armenia

14.40-15.00
Experience from Georgia 656 Kb (.pdf) загрузите русскую версию
Paata Imnadze, Georgia

15.30-15.50
Experience from Kyrgyzstan 265 Kb (.pdf) загрузите русскую версию
Joldosh Kalilov, Kyrgyzstan

15.50-16.10
Experience from Tajikistan 874 Kb (.pdf) загрузите русскую версию
Shamsiddin Jabirov, Tajikistan

16.10-16.30
Experience from Uzbekistan 1,943 Kb (.pdf) загрузите русскую версию
Erkin Musabaev, Uzbekistan

Thursday, March 16, 2006

SESSION 5  Prevention and control of perinatal HBV transmission: country status and experiences  – continued

Chair: Daniel Lavanchy and John Ward

09.00-09.30
Hepatitis B vaccination of newborns in rural China: evaluation of an outside-the-cold-chain delivery strategy 590 Kb (.pdf) загрузите русскую версию
Lixia Wang, Beijing, PR China

09.30-10.00
Improving the hepatitis B birth dose in Indonesia, Vietnam, and Cambodia 1,015 Kb (.pdf) загрузите русскую версию
Carib Nelson, Seattle, United States

10.00-10.30
WHO recommendations and guidelines for the prevention of perinatal hepatitis B and use of hepatitis B vaccines 288 Kb (.pdf) загрузите русскую версию
Steven Wiersma, Geneva, Switzerland

Session 6 Mother-and-child Health

Chair: Daniel Lavanchy and John Ward

11.00-11.30
Hepatitis B vaccination and HBIg administration policies implemented for premature babies – vaccines concurrently administered with the hepatitis B vaccine birth dose 531Kb (.pdf) загрузите русскую версию
Vassiliki Papaevangelou, Athens, Greece

11.30-11.45
Introduction to the workshops
Pierre Van Damme, Antwerpen, Belgium

12.00-14.00
Lunch

Session 7 Workshops on how to prevent perinatal HBV transmission

Chair workgroup A: Andrei Lobanov and Michael Favorov
Chair workgroup B: Selim Badur and Daniel Shouval

14.00-17.00
Topics discussed in the workshops:
- Results from the country questionnaire: current situation, thresholds, evaluation methods, indicators used, …
- How do countries monitor the administration of the first dose and the timeliness of the first dose?
- Is there information available regarding the price per dose of hepatitis B vaccine your country is currently paying?
- What are the three most important contraindications for hepatitis B vaccination of newborns?
- Management of waste disposal.
- Storing hepatitis B vaccine at the recommended temperature.
- Country experiences: lessons learnt, opportunities, and outreach systems.
- How can hepatitis B vaccination fit into overall mother-and-child health programmes?
- Contraindications for newborn hepatitis B immunisation – examples from participating countries.

Friday, March 17, 2006

Session 8 Feedback form the workshops

Chair: Alessandro Zanetti and Harold Margolis

What is feasible? What are the thresholds? What is to be recommended and what is to be improved?  How should be communicated in this context at country level? What is needed in terms of advocacy? Lessons learnt. How to implement the recommendations.

09.00-09.20
Feedback from Workshop 1

09.30-09.50
Feedback from Workshop 2

Session 9 Conclusions of the meeting and closing remarks

Chair: Mark Kane and Steven Wiersma

10.30-11.30
Conclusions and summary of the meeting 123 Kb (.pdf)  загрузите русскую версию
David FitzSimons,  Geneva, Switzerland

11.30 Close of the meeting

Tags: